Status:
TERMINATED
PK of Piperacillin/Tazobactam in Adults Undergoing ECMO
Lead Sponsor:
Columbia University
Conditions:
Acute Respiratory Failure With Hypoxia
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygen...
Detailed Description
In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs m...
Eligibility Criteria
Inclusion
- Patients 18 years of age or older
- Initiated on VV ECMO for acute respiratory distress syndrome
- Receiving piperacillin/tazobactam
Exclusion
- Pregnancy
- Massive blood transfusion (10 units or more of of PRBC) within a 24-hour period
- Prisoners
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 24 2024
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03467854
Start Date
January 1 2019
End Date
September 24 2024
Last Update
September 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital
New York, New York, United States, 10032